A Study on Ivonescimab Plus Chemotherapy as Neoadjuvant Therapy for Borderline Resectable Pancreatic Cancer

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 28, 2025

Primary Completion Date

April 28, 2026

Study Completion Date

March 28, 2027

Conditions

Pancreatic Cancer

Interventions

DRUG

AK112

All enrolled subjects will receive Ivonescimab（AK112，a PD-1/VEGF bispecific antibody，20mg/kg Q3W) in combination with gemcitabine and nab-paclitaxel

Trial Locations (1)

RECRUITING

Tianjin Cancer Hospital Airport Hospital, Tianjin

All Listed Sponsors

lead

Tianjin Medical University Cancer Institute and Hospital

OTHER